Case study

CTC and Dicot Pharma accelerate early-phase trial with Viedoc

Challenge 

Dicot Pharma aimed to move quickly from its successful first-in-human study to an early-phase (Phase 2a) efficacy clinical trial for its novel erectile dysfunction therapy. Building on its previous collaboration with Clinical Trial Consultants (CTC), the team needed to efficiently capture patient data from five international sites. 

Solution  

For the 156-patient Phase 2a trial, using Viedoc’s clinical EDC and ePRO tools, they could streamline workflows, capture patient-reported outcomes efficiently, and introduce dynamic randomization for the first time. 

Result

The Dicot Pharma, CTC, and Viedoc  partnership delivered a high-quality Phase 2a trial with diary compliance > 90% and reliable data supported by Viedoc’s integrated dynamic randomization. The platform’s fast setup and ease of use kept the study on its tight timelines, accelerating the market readiness of this new therapy.  

December 16, 2025

Biopharmaceutical company Dicot Pharma set out to advance its new therapy from its first-in-human study to Phase 2a in record time. Building on the successful first-in-human study run with CRO Clinical Trial Consultants using the Viedoc platform—including Viedoc Clinic (EDC) and Viedoc Me (ePRO)—the study team achieved rapid startup, strong patient compliance, and seamless execution across five sites in two countries, proving how collaboration, speed, and reliability drive success in early-stage drug development.

Collaboration across sponsor, CRO, and technology vendor 

Dicot Pharma, a Swedish biopharmaceutical company based in Uppsala, Sweden, is developing a new therapy for erectile dysfunction. The company had already completed a first in human trial with Swedish CRO Clinical Trial Consultants (CTC), a Viedoc partner also located in Uppsala. With a well-established collaboration already in place, and having used Viedoc together in that study, Dicot Pharma and CTC quickly launched a Phase 2a study with 156 patients across five of CTC’s own sites—four in Sweden and one in the Netherlands. This familiarity with Viedoc meant that everyone on the team was already comfortable with the system and confident in its reliability and accuracy. 

Because CTC could use their own and operated sites, it meant a quick startup, eliminating the typical long contracting cycles. The CRO and sponsor again selected Viedoc Clinic (EDC) and Viedoc Me (ePRO) to collect and manage patient data.  

Managing multi-site early-phase clinical trials efficiently 

While multi-site, multi-national studies can be challenging, the team was able to launch the phase 2a study quickly. According to Sofia Lyxell, Team Coordinator for the eCRF Manager Group at CTC, “We reused much of the foundation from the first study, saving significant time. And thanks to Viedoc, we can build and validate an eCRF in just a few weeks. Its flexibility and support allow us to respond quickly to sponsor needs.” 

Charlotta Gauffin, the CSO at Dicot Pharma, agreed, saying, “The process was very smooth. We could communicate directly, reuse what worked from the first study, and track progress in real time. Viedoc made it easy to go into the system and do a little bit of ‘shadow monitoring,’ so I could always be aware of our progress.” 

The team also leveraged dynamic randomization for the first time in this study, which helped ensure trustworthy results across all five sites. 

Clinical research professional using a laptop, concept for Viedoc EDC software in early-phase clinical trials
Patient entering data on a tablet, representing electronic patient-reported outcomes (ePRO) in clinical trials with Viedoc Me

User-friendly ePRO and EDC drive high patient compliance 

While geographic diversity helped capture a broad sample of patients, it also introduced a language barrier. This highlighted the need for a data collection and management system that easily supports multi-language translations—a key feature of Viedoc Clinic and Viedoc Me. The platform’s ability to translate 50+ languages makes it easier for users to enter their diary information into the ePRO, while also enabling the study team to assess results in any language they prefer. 

Some patients were seniors who may not have been comfortable with online account creation and login. Therefore, CTC’s backup plan involved capturing important questionnaire data using paper forms. In practice, however, most patients preferred Viedoc Me’s electronic diary for capturing patient-reported outcomes, according to Sofia. Not only is it easy to use, she said, but “More study patients now prefer to have an electronic diary and avoid having papers to remember to bring when visiting the clinic.” As a result of its user-friendly design for data collection, diary compliance rates in the Phase 2a trial exceeded 90%. 

The system’s user-friendly nature extends to all aspects of the Viedoc experience, including access to technical support. “Support answers within a day. That’s invaluable when timelines are tight,” Sofia explains. “Other vendors can take several days or more just to reply, but with Viedoc we get immediate responses.” 

Streamlining early-phase trials through collaboration 

The partnership between sponsor, CRO, and technology provider demonstrates how scientific expertise, operational agility, and digital tools can accelerate early-stage trials while supporting both patients and site teams. This case study highlights how modern clinical data technology can accelerate early-phase research across multiple sites. 

“The relationship was excellent—very, very smooth,” Charlotta recalled. “For early-stage efficacy studies, that combination of speed, reliability, and collaboration makes all the difference.” 

Team collaborating in a meeting, illustrating CTC and Dicot Pharma managing multi-site clinical trials with Viedoc

It's a user friendly EDC with ease of implementing changes. The customer support is quick. I use it frequently for studies. There are multiple features compared to other EDC which provide ease of integration of all the expectation.

Ankit S.

star star star star star

October 06, 2023

Leader G2 badge for Fall 2024